| Detailed information |
|---|
| CancerLivER ID | 2202 |
| Biomarker | AFP, BMK, (with cut off 1.25 of AFP in serum and 0.25 BMK in urine) |
| Biomarker Name/Symbol (given in Publication) | sAFP and uBMK (with cut off 1.25 of sAFP and 0.25 uBMK) |
| Biomolecule | Protein |
| Subject | Human |
| Degree of Validity | combining urine biomarkers (uBMK) values and serum AFP (sAFP) level, a new classification model has been proposed for more efficient HCC screening; but not validated on independent dataset |
| Experimental Condition | HCC v/s Non-HCC |
| Cancer type | Hepatocellular carcinoma |
| Regulation | NA |
| Level of significance | NA |
| Source | Serum and Urine |
| PMID | 29152526 |
| Type of Biomarker | Diagnostic |
| Pathway | NA |
| Cohort | 203 non-HCC patients either cirrhosis (106) or hepatitis (97) and 84 HCC patients |
| Sensitivity | 90.30% |
| Specificity | 90.50% |
| Accuracy | NA |
| AUC | 0.9 |
| Disease | Human HCC |
| Year of Publication | 2017 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |